- Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies
Felice Gragnano et al, 2018, Atherosclerosis CrossRef - Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation
Angelos D. Karagiannis et al, 2018, Curr Atheroscler Rep CrossRef - PCSK9: A novel inflammation modulator in atherosclerosis?
Zhi-Han Tang et al, 2018, J Cell Physiol CrossRef - The immune functions of PCSK9: Local and systemic perspectives
Xing Liu et al, 2019, J Cell Physiol CrossRef - Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality
Gang Wang et al, 2019, BioMed Research International CrossRef - Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines
Shijie Liu et al, 2019 CrossRef - PCSK9 inhibitors for treating hypercholesterolemia
Andrea Pasta et al, 2020, Expert Opinion on Pharmacotherapy CrossRef - Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes
Ying Tang et al, 2020, Cardiovasc Diabetol CrossRef - Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress
Leila Safaeian et al, 2020, Archives of Physiology and Biochemistry CrossRef - Ticagrelor suppresses oxidized low‑density lipoprotein‑induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE‑/‑ mice via downregulation of PCSK9
Xiaodong Xia et al, 2018, Mol Med Report CrossRef - Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice
Lei Wang et al, 2018, Int J Mol Med CrossRef - Exosomal MALAT1 derived from oxidized low-density lipoprotein-treated endothelial cells promotes M2 macrophage polarization
Chaoyang Huang et al, 2018, Mol Med Report CrossRef - An Update on the Role of PCSK9 in Atherosclerosis
Ece Yurtseven et al, 2020, JAT CrossRef - Downregulation of LncRNA NORAD promotes Ox-LDL-induced vascular endothelial cell injury and atherosclerosis
Weihua Bian et al, 2020, Aging CrossRef - Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall
Yanan Guo et al, 2020, J Cell Physiol CrossRef - PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
Qianyun Guo et al, 2020, Front. Genet. CrossRef - PCSK9 and atherosclerosis: Looking beyond LDL regulation
Rosetta Ragusa et al, 2020, Eur J Clin Invest CrossRef - Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
Klaus-Dieter Schlüter et al, 2020, Front. Physiol. CrossRef - PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Aureli Luquero et al, 2021, Front. Cardiovasc. Med. CrossRef - PCSK9 Biology and Its Role in Atherothrombosis
Cristina Barale et al, 2021, IJMS CrossRef - Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
Suowen Xu et al, 2021, Pharmacol Rev CrossRef - Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients
Evangelia Dounousi et al, 2021, Oxidative Medicine and Cellular Longevity CrossRef - Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Bayan Moustafa et al, 2021, Journal of Stroke and Cerebrovascular Diseases CrossRef - Focus on ferroptosis, pyroptosis, apoptosis and autophagy of vascular endothelial cells to the strategic targets for the treatment of atherosclerosis
Xiaoyan Lin et al, 2022, Archives of Biochemistry and Biophysics CrossRef - Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
Patrice Marques et al, 2022, Biomedicine & Pharmacotherapy CrossRef - Rotigotine protects against oxidized low-density lipoprotein(ox-LDL)-induced damages in human umbilical vein endothelial cells(HUVECs)
Hui Kang et al, 2021, Bioengineered CrossRef - Galectin‐3 exacerbates ox‐LDL‐mediated endothelial injury by inducing inflammation via integrin β1‐RhoA‐JNK signaling activation
Xiumei Chen et al, 2019, Journal Cellular Physiology CrossRef - Protective Mechanism of Proprotein Convertase Subtilisin-Like Kexin Type 9 Inhibitor on Rats with Middle Cerebral Artery Occlusion-Induced Cerebral Ischemic Infarction
Shengxiong Pu et al, 2022, Computational Intelligence and Neuroscience CrossRef - Therapeutic potential of the Proprotein Convertase Subtilisin/Kexin family in vascular disease
Bianca E. Suur et al, 2022, Front. Pharmacol. CrossRef - Silencing YY1 Alleviates Ox-LDL-Induced Inflammation and Lipid Accumulation in Macrophages through Regulation of PCSK9/ LDLR Signaling
Zhengyao Qian et al, 2022, J. Microbiol. Biotechnol. CrossRef - The Role of Neutrophils in Lower Limb Peripheral Artery Disease: State of the Art and Future Perspectives
Giacomo Buso et al, 2023, IJMS CrossRef - Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
Minglu Ma et al, 2023, Front. Cardiovasc. Med. CrossRef - Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Andrew S. Bell et al, 2023, Neuroscience & Biobehavioral Reviews CrossRef - The evolving landscape of PCSK9 inhibition in cancer
Palak P. Oza et al, 2023, European Journal of Pharmacology CrossRef - PCSK9 Inhibitors as Adjunctive Therapies in Hypercholesterolemia: Benefits, Limitations, and Possible Alternatives
Mawieh Hamad et al, 2023, Advanced Therapeutics CrossRef - PCSK-9 inhibitors: a new direction for the future treatment of ischemic stroke
Lin Zhou et al, 2024, Front. Pharmacol. CrossRef - Effects of PCSK9 on thrombosis and haemostasis in a variety of metabolic states: Lipids and beyond (Review)
Shan Chong et al, 2024, Int J Mol Med CrossRef - The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol
Mieczysław Dutka et al, 2024, Heart Fail Rev CrossRef - Direct Impact of PCSK9 on SMC Senescence and Apoptosis: A New Focus in Cardiovascular Diseases
Xiaoping Wang et al, 2024, ATVB CrossRef - The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis et al, 2024, Metabolites CrossRef - Investigating the Relationship Between Lipid-Lowering Agents and the Complications of Diabetic Retinopathy
Hejin Jeong et al, 2024, Ophthalmic Surg Lasers Imaging Retina CrossRef - Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9
Alexander M. Cao Zhang et al, 2024, Eur J Clin Investigation CrossRef - Polyenylphosphatidylcholine alleviates cardiorenal fibrosis, injury and dysfunction in spontaneously hypertensive rats by regulating Plpp3 signaling
Yongqiao Zhang et al, 2024, Front. Cardiovasc. Med. CrossRef - The Link between miRNAs and PCKS9 in Atherosclerosis
Mirjana T. Macvanin et al, 2024, CMC CrossRef